Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Helius Medical Technologies Inc (NQ: HSDT )

8.200 +0.150 (+1.86%)
Streaming Delayed Price Updated: 2:10 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Helius Medical Technologies Inc

< Previous 1 2 3 4 5 Next >
Helius Medical Technologies Announces DMEPOS Accreditation for PoNS
-- Critical initial step toward US reimbursement -- 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Why Oxford Industries Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Baosheng Media Group Holdings Limited (NASDAQ: BAOS) shares climbed 91.2% to $10.81. 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday. 
Via Benzinga
Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Tech: Q1 Earnings Insights
Via Benzinga
Earnings Outlook For Helius Medical Tech
Via Benzinga
Helius Medical Tech's Return On Capital Employed Insights
Via Benzinga
Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release First Quarter 2023 Financial Results on May 11, 2023
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685
MS, Stroke and mmTBI Cover Broader Set of Indications Across North American Markets 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Earnings Preview For Helius Medical Tech
Via Benzinga
Looking Into Helius Medical Tech's Return On Capital Employed
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning! 
Via InvestorPlace
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
From Helius Medical Technologies, Inc.; HealthTech Connex Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke
-- PoNS already approved in Canada for treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI) and gait deficit due to mild and moderate symptoms from Multiple... 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Present at the 35th Annual ROTH Conference
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting
Physical therapists in attendance can enhance their skillset with free on-site PoNS training 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis
PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk
New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps 
From Helius Medical Technologies, Inc.
Via GlobeNewswire
Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
From Helius Medical Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.